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ARTICLE OPEN
Dopamine affects short-term memory corruption over time in
Parkinson’s disease
Sean James Fallon1,2, Matthew Gowell1, Maria Raquel Maio 1 and Masud Husain 1,3
Cognitive deﬁcits are a recognised component of Parkinson’s disease (PD). However, particularly within the domain of short-term
memory, it is unclear whether these impairments are masked, or caused, by patients’ dopaminergic medication. The effect of
medication on pure maintenance in PD patients has rarely been explored, with most assessments examining maintenance
intercalated between other executive tasks. Moreover, few studies have utilised methods that can measure the quality of mental
representations, which can enable the decomposition of recall errors into their underlying neurocognitive components. Here, we ﬁll
this gap by examining pure maintenance in PD patients in high and low dopaminergic states. Participants had to encode the
orientation of two stimuli and reproduce these orientations after a short (2 s) or long (8 s) delay. In addition, we also examined the
performance of healthy, age-matched older adults to contextualise these effects and determine whether PD represents an
exacerbation of the normal ageing process. Patients showed improved recall OFF compared to ON their dopaminergic medication,
but only for long-duration trials. Moreover, PD patients OFF their medication actually performed at a level superior to age-matched
controls, indicative of a paradoxical enhancement of memory in the low dopaminergic state. The application of a probabilistic
model of response selection suggested that PD patients made fewer misbinding errors in the low, compared with high,
dopaminergic state for longer-delay trials. Thus, unexpectedly, the mechanisms that prevent memoranda from being corrupted by
misbinding over time appear to be enhanced in PD patients OFF dopaminergic medication. Possible explanations for this
paradoxical effect are discussed.
npj Parkinson’s Disease            (2019) 5:16 ; https://doi.org/10.1038/s41531-019-0088-2
INTRODUCTION
Parkinson’s disease (PD), even in the absence of dementia, is now
known to be associated with a variety of cognitive control deﬁcits,
particularly in the domains of planning,1,2 attention,3 working
(short-term) memory4–6 and learning.7,8 Impaired performance on
these processes is commonly assumed to result from dopaminer-
gic denervation of the basal ganglia.9,10 However, PD is also
associated with widespread pathology involving other neuro-
transmitter systems: serotonergic, cholinergic and noradrener-
gic.11–13 Disruptions to the integrity of these non-dopaminergic
systems may also be responsible for behavioural abnormalities in
patients.14
Researchers have attempted to isolate the role of dopamine in
causing cognitive control impairments in PD by testing patients
ON and OFF their dopamine-enhancing medication.15–18 In the
ﬁeld of working memory (WM), these studies have produced
conﬂicting results. Some report no effect of medication,19 whereas
others have found both impaired20–22 or even improved18
performance. Researchers have attempted to account for these
divergent ﬁndings by hypothesising that dopaminergic medica-
tion can have separate, possibly opposing effects, on different
mnemonic subprocesses.
One prominent idea is that dopaminergic medication has
different effects on maintenance versus manipulation of items in
WM.23 This proposal has recently received support and elabora-
tion. PD patients were found to have an enduring, dopamine-
independent deﬁcit in maintaining information over longer
retention periods. In contrast, impairments in the proﬁciency of
manipulating information (speciﬁcally updating WM contents or
protecting them from distractors—ignoring) were found to
be ameliorated by dopaminergic medication.24 Moreover, by
using delayed, analogue report measures—in which the features
of a memoranda (e.g., orientations) need to be reproduced—it
was possible to apply a computational model to uncover the
source of these errors.
In that model,25 errors in recall can result from changes in the
precision which memoranda are stored, misbinding features
belonging to different items (a form of interference) or guessing
(chance). Misbinding errors occur when the different components
of memoranda are erroneously combined, e.g., after encoding a
red triangle and a blue square, the square is reported as being red.
In contrast, guessing (or chance) errors occur when the reported
memoranda bear no statistical relationship to the studied items.
Application of this model to the data from patients tested ON and
OFF their medication revealed that dopamine and PD affected
different components in a task-dependent manner.
Withdrawing patients from their medication impaired ignoring
and updating through increasing the number of guess responses.
Whereas, independent of medication state, PD patients had a
decrement in precision of recall for longer retention periods. Thus,
these ﬁndings suggest that having PD affects the maintenance of
information through increasing decay across time, whereas being
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on dopamine allows mental representations to be robust, even in
the presence of irrelevant information. Neither PD nor dopamine
affected the level of misbinding. This suggests dopamine has very
little capacity to affect the corruption of items in WM, a position
strengthened by other ﬁndings,26,27 but see ref. 28 However, the
generalisability of these ﬁndings has not been assessed and other
explanations for the ﬁndings could not be ruled out.
First, unlike prior investigations of WM in PD patients,27 the
previous study did not obtain a measure of sensorimotor
performance in age-matched controls or patients ON and OFF
their medication. Thus, it needs to be demonstrated that patients
can have impaired maintenance performance in the absence of
any co-occurring sensorimotor deﬁcit. Second, it could also be
argued that the results of the previous study24 are insufﬁcient to
exclude a role for dopamine in short-term recall. The previous
assessment of maintenance was sandwiched between tasks that
required irrelevant information to be supressed (ignore or update).
Thus, some of the apparent deﬁcits of patients on maintenance
trials might be explained by switching effects (see ref. 29) and/or
expectations (which are known to affect the allocation of
mnemonic resources).30
Third, the maximum maintenance period in the previous study
was 6 s. This may be insufﬁcient time for a deﬁcit in the robustness
of mental representations to materialise. Though the mechanisms
responsible for the effect are debated,31–33 it is well known that
recall performance can deteriorate with increasing retention
periods. Thus, ideally, longer maintenance periods need to be
assessed. Finally, to enable the results of the previous study24 to
be generalised, it is necessary to test WM using an alternative set
of parameters. In the previous study, the role of dopamine in
affecting spatial WM was not examined. In that investigation the
spatial location of the stimuli was irrelevant (did not have to be
recalled), but could still inﬂuence the results through the
obligatory manner in which spatial information consumes
mnemonic resources34,35 and affects the probability of misbinding
events occurring.36 This issue may be particularly important in PD,
where it has been argued that spatial WM is prominently affected
by the disease37,38
Here, we seek to examine these hypotheses by testing patients’
pure maintenance abilities in a novel paradigm (Fig. 1).
Participants had to remember the orientations of two stimuli
presented on the left and right of the screen. After a short (2 s) or
long (8 s) delay, one of these items—indicated here by the spatial
location of the probe cue—had to be recalled. A ‘zero’ delay
condition in which the responses had to be made while the
memoranda remained on the screen was also included to rule out
sensorimotor confounds.
RESULTS
Recall was examined in patients using a 2 × 3 repeated measures
ANOVA with medication (ON vs OFF) and task (sensorimotor,
2000- and 8000-ms delay) as within-subject factors. This analysis
revealed signiﬁcant effects of task on recall (F(2,38)= 76.40, p <
0.0001, ω2= 0.54), with recall error increasing in both the 8000-ms
(t(19)= 8.98, p(Holm) < 0.0001, d= 2.00) and 2000-ms (t(19)= 9.84,
p(Holm) < 0.0001, d= 2.00) delay compared with the sensorimotor
condition. Recall error was also signiﬁcantly impaired for the 8000-
ms compared with the 2000-ms delay (t(19)= 3.38, p(Holm)= 0.003,
d= 0.75). Thus, there was evidence for the decline of memory
from the short- to the long-retention periods.
Medication state also had a signiﬁcant main effect on recall (F
(1,38)= 10.48, p= 0.004, ω2= 0.039) with patients OFF their
dopaminergic medication showing signiﬁcantly improved recall
compared with patients ON their medication. Medication was
found to signiﬁcantly interact with task (F(2,38)= 7.17, p= 0.002,
ω2= 0.028). Importantly, there was no signiﬁcant effect of drug
on recall in the sensorimotor condition (t(19)= 0.791, p= 0.438,
d= 0.17). To conﬁrm that medication differentially affected
performance in the mnemonic conditions, a separate 2 × 2
repeated measures ANOVA was performed with drug (OFF, ON)
and delay (2 s, 8 s) as within-subject factors. A signiﬁcant
interaction between drug and delay was found (F(1,19)= 6.52,
p= 0.019, ω2= 0.01). This interaction was due to medication
signiﬁcantly impairing recall at the long delay (t(19)= 3.49, p=
0.002, d= 0.78), but having no signiﬁcant effect on recall for the
short delay (t(19)= 1.64, p= 0.116, d= 0.37) (Fig. 2).
There was no signiﬁcant difference between age-matched
controls and patients OFF or ON medication in terms of
performance on the sensorimotor task (OFF vs controls, t(46)=
0.656, p= 0.515, d= 0.19; ON vs controls, t(46)= 0.086, p= 0.93,
d= 0.025). To contextualise the above medication effects, we
compared, separately, the performance of patients OFF and ON
Fig. 1 Schematic representation of the task. Participants were
presented with two arrows on the left and right side of the screen
(2000ms) and had to retain the orientations of these items. In the
memory conditions, a blank screen followed for either 2000 or
8000ms. After this, a probe item (randomly offset arrow) appeared
on the lower left or right side of the screen. Participants had to
rotate the probe item until it matched the remembered orientation.
The spatial position of the probe indicated which item needed to be
recalled, e.g., a probe on the left required the orientation of the left
item to be recalled. In the sensorimotor control condition, however,
the original stimuli remained on the screen during the probe phase
and participants had to simply match the orientations
Fig. 2 Orientation error recall and sensorimotor control matching
performance for patients (split according to medication status: ON
vs OFF) and age-matched controls. Error bars (centered on the mean
for each condition) reﬂect the standard error of the mean
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their medication with healthy age-matched controls. We per-
formed two separate mixed 2 × 2 ANOVAs with repeated
measures on delay (2 or 8 s) and group (the respective patient
group or controls) as a between-subject variable. Recall in patients
ON their medication was not signiﬁcantly different compared with
age-matched controls (F < 1) and group differences in recall did
not signiﬁcantly vary as a function of task (F(1,46)= 2.16, p= 0.15,
ω2= 0.003). However, comparison of patients’ performance OFF
medication against healthy older adults, revealed signiﬁcantly
better performance in the patient group (F(1,46)= 6.26, p= 0.016,
ω2= 0.1). The effect of group did not signiﬁcantly vary as function
of delay (F < 1).
In order to deconstruct the cognitive mechanisms behind the
effect of medication on recall, we applied a computational model
of response selection to the data. First, we examined the effects of
medication in PD patients.
Kappa
This parameter refers to the precision (or concentration of the
response orientation around the target orientation) of recall
(Supplementary Fig. 1). Medication did not signiﬁcantly affect
kappa values for either short (W= 148, p= 0.11, rb= 0.41) or long
delays (W= 142, p= 0.177, rb= 0.35).
Target
Next, we examined the proportion of trials in which the response
was centred on the target orientation, i.e. the orientation of the
probed item. Medication did not signiﬁcantly affect the probability
for responding to the target orientation for short delay trials (W=
129, p= 0.388, rb= 0.23), but it did signiﬁcantly increase the
probability of responding to the target for long durations (W=
166, p= 0.021, rb= 0.58). Thus, OFF medication patients were
more likely to make responses towards the target orientation than
when ON medication (Supplementary Fig. 2).
Misbinding
This parameter captures the extent to which participants are
responding to the non-target orientation (the other item
participants were remembering but were not asked to recall).
This is a measure of the interference of the other item stored in
WM on recall performance. There was no signiﬁcant effect of
medication on misbinding for short duration trials (W= 104, p=
0.985, rb= 0.01), but patients OFF were less likely to make these
types of errors than when ON their medication during long-delay
trials (W= 45, p= 0.025, rb= 0.57). Thus, medication increased
misbinding errors in patients (Fig. 3).
Guessing
In contrast to misbinding, this parameter reﬂects the likelihood
that participants’ responses are not concentrated on any
orientation (Supplementary Fig. 3). Here, unlike the misbinding
results, there were no signiﬁcant effects of medication on guesses,
either for short (W= 85, p= 0.475, rb= 0.19) or long durations
(W= 102, p= 0.927, rb= 0.029).
In summary, the modelling evidence suggests that patients’
poorer recall when ON their dopaminergic medication, compared
with OFF, was due to an increase in the number of misbinding
responses. We also undertook some separate analyses to
investigate if increased misbinding in patients can also be found
using a model-free analysis. Here, we simply looked at the
proportion of responses that were closer to the target orientation
or non-target orientation. A drug (OFF, ON) by delay (2000 ms,
8000ms) repeated measures ANOVA revealed that there indeed
was a main effect of drug on the proportion of misbinds: patients
ON their medication made signiﬁcantly more responses closer to
the non-target than the target orientation (F(1,19)= 4.43, p=
0.049, ω2= 0.021). There was no effect of delay period or
interaction between delay period and time (Fs < 1),
For completeness, we also examined the extent to which these
parameters differed between patients (ON and OFF their
medication) and controls. Neither patient group (ON or OFF their
medication) signiﬁcantly differed in the level of target nor
misbinding response for long-duration trials (see Supplementary
Table 3). In line with the overall superior performance of patients
OFF medication compared with controls across both delays, there
was some evidence that this group of patients showed improve-
ments across multiple parameters of our model compared with
controls. Controls, compared with patients OFF, showed a
reduction in kappa (lower precision; p= 0.038) and higher
guessing (p= 0.031) rates for the short-duration trials. But these
differences were not replicated in the long-delay trials. Thus,
cumulatively, when comparing patients OFF with controls, several
factors may be responsible for driving the superior performance of
patients OFF compared with controls.
Reaction times
No differences were found for response latency (time to complete
responding) between the groups and medication conditions
(Supplementary Table 4; Supplementary Materials).
We also examined whether there were any differences in digit
span as a function of medication or disease state. There was no
signiﬁcant difference in digit span between patients ON and OFF
their medication (t(19)= 0.553, p= 0.58, d= 0.12). Neither group
differed in their digit spans compared with controls (OFF vs
controls (t(46)= 0.70, p= 0.491, d= 0.20; ON vs controls, t(46)=
0.50, p= 0.62, d= 0.146). Thus, on this clinical measure, there was
no evidence that patients (ON or OFF their medication) and
controls differed in their basic mnemonic abilities.
DISCUSSION
This study has revised our understanding of short-term memory
abilities in PD. Rather than showing superior performance ON
dopaminergic medication, patients’ recall was signiﬁcantly
enhanced, in a delay-dependent manner, when they were OFF
medication. Moreover, PD patients OFF their medication were
performing signiﬁcantly better than healthy, age-matched con-
trols. Application of a computational model of response selec-
tion25 to patients’ pattern of responses revealed that this superior
Fig. 3 Probability of misbinding ON and OFF dopaminergic
medication. Probability of misbinding (reporting the orientation of
the non-probed item) according to medication status and delay.
Error bars (centred on the mean for each condition) reﬂect the
standard error of the difference between OFF and ON patients for
each condition
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performance by patients OFF dopaminergic medication was due
to a decrease in the likelihood of misbinding errors for the longer
retention period, that is, they were less likely to report the
orientation of the non-probed target orientation. However, the
superior performance of patients OFF their medication (compared
with controls) appeared to be due to several factors, i.e., improved
precision and reduced guessing.
In addition to dopamine, PD is associated with a variety of
disturbances to a wide range other neurochemical systems.12,13,39
One of the goals of research into patients’ cognitive deﬁcits has
been to attempt to fractionate the neural substrates responsible
for causing these impairments in order to tailor future
interventions.
In order to isolate the causal role that dopaminergic abnorm-
alities have in producing patients’ cognitive deﬁcits, researchers
have tested patients ON and OFF their medication. However,
previous studies have produced conﬂicting results, with medica-
tion improving neural and behavioural indices of planning,
attention and WM,15,18,40 but impairing ﬂexible responding to
reward and punishment.7,8
In attempting to explain these discrepancies, it has been argued
that these differential effects of dopaminergic medication are due
to the uneven pattern of dopaminergic depletion across fronto-
striatal circuits that are separately responsible for cognitive,
affective and motoric functions.9,41,42 Medication is argued to
improve those functions dependent upon the most dopamine-
depleted, i.e., dorsal fronto-striatal circuits, but impairs those
functions that recruit the less severely affected ventral circuitry. As
such, those WM functions that are particularly reliant on dorsal
fronto-striatal circuits, such as ignoring and updating,43,44 are
regularly found to be improved by dopaminergic medication.45
However, even within depleted dorsal areas, dopamine levels
need to be tightly calibrated to maintain optimal performance. For
example, decades of research has revealed that there is an
inverted-U shape function linking the level of prefrontal dopami-
nergic stimulation with WM performance, with either too little or
too much dopamine impairing recall.46–48
Despite suffering from aberrant signals from the dopamine-
depleted dorsal striatum, there is ample evidence to suggest that
prefrontal dopamine levels are upregulated in PD patients.
Speciﬁcally, positron emission tomography (PET) measurements
report excess, supranormative, dopamine levels in fronto-parietal
areas.49–51 Indeed, spatial WM ability—speciﬁcally confusing the
locations of items across recall episodes—has been argued to
display an inverted-U relationship with putative prefrontal
dopamine levels in PD patients.52 Patients with either putatively
low or high dopamine levels were found to make more errors than
the group with intermediate dopamine levels.52 Thus, it could be
hypothesised that the superior performance of PD patients OFF
their medication is explained by this group having the task-
speciﬁc optimal level of dopamine to perform the current task. In
contrast, medicated PD patients or healthy age-matched controls,
may have diminished performance due to having, respectively,
too high or low dopamine levels. The contention that older adults,
even in the absence of PD, may have reduced dopamine levels, is
supported by research showing that the level of this neurotrans-
mitter declines with age.53 Therefore, the performance of controls
and medicated PD patients reﬂects the performance from being
situated, respectively, on the left- and right-hand limb of an
inverted-U-shape function between dopamine and WM
performance.
Improved performance on a WM task in patients OFF their
medication has previously been reported.20 However, there are
some notable differences. Whilst distracter resistance (as
indexed with reaction time) in PD patients improved ON
medication, digit span was impaired when OFF medication.
Based on prior ﬁndings that linked distracter resistance to
prefrontal activity54 and digit span to striatal dopamine,55 the
authors interpreted this effect as occurring due to an imbalance
in the dopamine levels between these regions. However, in the
present study we found no evidence for impaired digit span in
PD patients as a function of dopaminergic state, perhaps
indicating different mechanisms are responsible for generating
the effects across these two studies.
Although the suggestion that patients OFF their medication
show superior WM abilities due to having optimal dopamine levels
to perform the task explains the overall pattern of recall
performance, it does not explain why it was misbinding levels
that were affected as opposed to precision. Previous studies have
not found that PD patients display an increase in misbinding
errors and that these types of errors are not modulated by
dopaminergic medication.24,26 Instead, rather than being affected
by disruption to fronto-striatal circuits and the main dopaminergic
projections that affect these regions, misbinding is thought to
stem from disruption to medial temporal lobe regions. This
hypothesis is based upon observations that misbinding levels
increase in groups that have, or are at risk of having, compromised
hipppcampi (see refs. 56–60). One potential reason for the
increased sensitivity of misbinding errors to dopaminergic
medication in this study is the relatively long retention period
that was used in this study. Corruption of recall due to misbinding
errors is known to increase with time.36,61 Thus, there may have
been greater scope for hippocampally mediated processes to
disrupt recall in the present experiment.
Importantly, as with the frontal lobe, there is some evidence for
heightened activity (as measured with functional magnetic
resonance imaging) in medicated PD patients whilst performing
cognitive tasks.62,63 Thus, it is possible that the absence of
medication reduces this excessive activity in the hippocampus.
Though it should be noted that this explanation is not mutually
exclusive with the above literature on fronto-striatal overdosing in
PD patients. There is an extensive and rich set of connections
between dopaminergic fronto-striatal and hippocampal regions,64
and it may be the disrupted communication between these
regions that is responsible for producing the effects observed in
the present study. Further research, perhaps combining PET with
behavioural techniques such as the one used here, is required to
answer this question more deﬁnitively.
There may also be a need to revise our conceptualisation of
cognitive impairment in PD patients on the basis of these ﬁndings.
Prominent theories focus on the role of gating information into
and out of WM in PD 65 usually foveate on this process occurring
at encoding or during processing some to-be-updated material.
However, the present results suggest that retrieval may also be a
dopamine-sensitive gating process, i.e., it could be hypothesised
that it is errors at retrieval, rather than maintenance, that are
responsible for generating the present results. Future studies will
be needed to examine this hypothesis.
Patients OFF their medication also performed consistently
better than controls at both delay periods, i.e., their superior
performance was not restricted to the long delay conditions.
Applying the computational model to the data did not reveal a
unique cognitive source of this difference in performance.
Differences in kappa (precision) and guessing were apparent at
short durations, but these differences were not present to the
same extent at longer durations. Thus, it is possible that the
overall difference in accuracy (angular error at recall) was driven
by multiple factors, which together produce differences in recall.
The neurochemical and receptor-speciﬁc mechanisms responsible
for this effect should be evaluated in future studies by
administering relevant agents, e.g., cabergoline to healthy older
adults and examining the effect it has on recall.
S.J. Fallon et al.
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METHODS
Study design
This study consisted of 20 patients with PD and 28 age-matched healthy
controls (see Table 1 for demographics). Participants were included in this
study, if they had normal or corrected-to-normal vision and were not
colour blind. Healthy participants were included if they had no history of
any neurological or psychiatric illness. All participants gave written
informed consent prior to participation. The study was approved and
consistent with all relevant local (University of Oxford and National Health
Service) regulations (REC no. 14/SC/0044).
A clinical diagnosis of idiopathic PD (according to the United Kingdom
Parkinson’s Disease Society Brain Bank Criteria66) was necessary to be
eligible to participate in this study. None of the participants were clinically
classiﬁed as having dementia. Cognitive function was also screened here
using the Addenbrooke's Cognitive Examination-III (ACE-III) and digit span
(a standard measure of verbal WM). Patients were tested in two morning
sessions: ON and OFF their dopaminergic medication (order counter-
balanced). Dopaminergic medication levodopa equivalent dose was
calculated using a standard algorithm [(Levodopa dose ×1.2 if COMT
inhibitor) (×1.2 if 10 mg of Selegiline or ×1.1 if 5 mg of Selegiline)]+
[Paramipexole × 400]+ [Cabergoline ×160].67 See Supplementary Materi-
als for more information (Supplementary Table 2).
Working memory task. We used a delayed report task to assess the quality
of WM representations. In these designs, participants must reproduce the
exact feature of a memoranda, e.g., orientation. This can give an indication
of the quality of recall.68
In this instantiation, participants were presented with two arrows, either
at the top left or right of the screen (2000ms). Then, in the short-term
memory conditions, after either a 2000- or 8000-ms delay, participants
were asked to recall the orientation of one of the items. Participants could
discern which item had to be recalled according to the spatial location of
the probe cue. The probe cue was an arrow presented in the lower left or
right of the screen surrounded by a white circle. The spatial location of the
cue (left or right) indicated which item had to be recalled, e.g., if the recall
cue appeared on the left side of the screen the orientation of the left arrow
had to be reproduced.
The initial orientation of the probe cue was randomly offset from the
target orientation. Participants had to rotate the arrow clockwise or
counter-clockwise (using the ‘A’ or ‘Z’) keys until they were satisﬁed it
matched the target orientation. Participants signiﬁed when they ﬁnalised
their decision regarding their reproduction of the orientation by pressing
the ‘Space’ bar. No feedback was presented.
Participants completed 192 trials (64 in each condition). In half of the
trials, the probe cue appeared on the left, and on the other half the right.
Patients completed the testing on two morning sessions, one ON their
usual medication and the other OFF their dopaminergic medication,
counterbalanced across drug status. Healthy controls performed one
session.
Data were analysed in JASP.69 The threshold for statistical signiﬁcance
was set at the conventional level (α= 0.05) and appropriate estimates of
effects size are also provided (e.g., Cohen’s d (d) for parametric pairwise
comparisons, rank biserial correlation (rb) for non-parametric contrast and
omega squared (ω2) for ANOVAs). All pairwise comparisons were evaluated
using two-tailed tests. Corrections applied to correct the alpha level for
multiple comparisons are indicated, e.g., p(Holm),
Quality of recall was assessed using mean angular error (absolute
angular difference between orientation of the target and response).
Repeated measures ANOVA 2 × 3 was used to examine the effect of the
within-subject factor medication (OFF, ON) and condition (sensorimotor
control, 2000- and 8000-ms delay). To clarify the results with respect to
control performance, two mixed ANOVA 2 × 2 were used to compare
patients (ON and OFF) with age-matched controls across delays (2000 and
8000ms).
Although an accurate measure of the quality of WM, the angular error of
recall is composed of distinct components.68 We have previously found
that the speciﬁc type of error participants make on these tasks can be
uncovered by applying a mixture model to the data.26,27 The speciﬁc
model25,70 decomposes recall into four components, represented in the
following equation:
p θ^
 
¼ αϕκ θ^ θ
 
þ
Xm
i¼1
βiϕκ θ^ φi
 
þ γ 1
2π
;
1. Precision (Kappa), reﬂecting the spread of responses around target
items (high kappa values reﬂect better recall; κ;).
2. Probability of responding to the target, with higher values indicating
a greater likelihood of responding to the target orientation (α).
3. Misbinding parameter, reﬂecting the probability that the orientation
of the non-probed item was reported, with higher values reﬂect a
greater probability of misbinding (β).
4. Guessing parameter indicating the proportion of responses in which
there is no systematic relationship between the response orienta-
tion and the target orientations (γ).
In the equation, θ^ is the responded orientation, p θ^
 
is the probability
of the responded orientation, ϕκ is a von Mises probability density function
centered on zero with concentration κ, m is the number of incorrect items
in the display (in this case 1, indexed by i), θ is the orientation of the target
angle, φi is the angle of the incorrect item, and α, βi, γ are proportions of
each component of the response distribution (satisfying αþPβi þ γ ¼ 1).
Thus, there are three free parameters, α, β, κ in the model.
As in previous studies,24 the models were ﬁt separately for each
participant, delay (2000, 8000ms) and each medication session (for
patients). For comparison across medication (OFF, ON), non-parametric
Table 1. Demographics, questionnaires and baseline cognitive measurements.
Measure Healthy elderly controls Parkinson’s disease Controls versus Parkinson’s disease P-value
n 28 20 n/a
Age 70.9 (±3.0) 70.5 (±5.8) 0.76
Gender (F/M) 16/12 8/12 0.24a
Handedness (R/L) 25/3 16/4 0.37a
Hoehn and Yahr stage n/a 1.95 (±0.2) n/a
UPDRS motor score ON n/a 24.0 (±10.6) n/a
UPDRS motor score OFF n/a 31.2 (±14.8) n/a
Change in motor score n/a 7.3 (±8.5) n/a
Levodopa equivalent dose (mg/24 h) n/a 500 (±284) n/a
Minutes since last dose, ON n/a 234.1 (±57.3) n/a
Minutes since last dose, OFF n/a 962.5 (±233.9) n/a
Global Cognition (ACE-III score) 95.4 (±4.6) 95.2(±3.4) 0.86
Digit span 21.4 (±3.8) 20.85 (±4.2) 0.63
All values are mean ( ± standard deviation)
ACE Addenbrooke’s cognitive examination III, n/a not applicable
aChi-squared test
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analyses (Wilcoxon signed-rank test) were used. For comparisons between
patients and controls, Mann–Whitney U tests were employed. Again, as
with previous studies, we used the Akaike Information Criterion (AIC) to
evaluate whether the model provided a good ﬁt to the data. Across all
groups and conditions, the full model (including the misbinding and
guessing parameters) provided the best ﬁt of the data (Supplementary
Table 1).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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